Jan 13 (Reuters) - Pediapharm Inc PDP.V :
* Sells its US rights to Naproxen suspension in a transaction valued at up to approximately US$4.25 million
* Says the prescription drug user fee assessment ("PDUFA") date is expected to be held in February 2016
* Will retain rights to Naproxen suspension in Canada and will continue to commercialize using its own infrastructure
* Terms include payment of $2.25 million in cash on closing, payment of $2.0 mnl conditional on Pediapharm being granted approval from FDA
* Source text for Eikon Further company coverage PDP.V